English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
News and events

01 May 2020 - COVID-19 and coagulation risk, the first Italian register of patients by the scientists of the Arianna Anticoagulation Foundation is born

The START-COVID-19 register is one of the activities supported by Italfarmaco and is part of GHEMAVID, the new platform of medical-scientific projects that the company makes available to the Scientific Community and to all Doctors in order to deepen their knowledge on COVID- 19 and counteract thromboembolic complications.

13 November 2019 - identification of new and highly selective inhibitors of histone deacetylase 6

The “Journal of Medicinal Chemistry” publishes a paper on the identification of new and highly selective inhibitors of histone deacetylase 6 (HDAC6) by the Italfarmaco drug discovery team.


10 September 2019 - World Drug Safety Congress Europe, 10-11 September 2019, Amsterdam

Invited speaker: Margherita D’Antuono, Corporate Pharmacovigilance Director, EU QPPV Italfarmaco S.p.A.

07 September 2019 - Bring your light for the World Duchenne Awareness Day

Italfarmaco is devoted to bring the light of hope into the world of Duchenne by committing to develop drugs to slow down the disease progression...

06 June 2019 - Award Ceremony of Le Fonti Awards, June 6th 2019

Award obtained:
Italfarmaco, Excellence of the Year Innovation & Leadership R&D Pharmaceutical Sector for being an Italian excellence in the pharmaceutical sector.

29 March 2019 - Italfarmaco Group is pleased to announce the marketing of GhemaXan, the first biosimilar of Enoxaparin Sodium developed and produced in Italy

25 February 2019 - Italfarmaco launches NUPERAL in Italy, the first drug as fixed combination of doxilamine succinate and pyridoxine hydrochloride authorized for the symptomatic treatment of nausea and vomiting during pregnancy

20 February 2019 - Gordon Research Conference on Cancer Genetics and Epigenetics

31 January 2019 - Italfarmaco rafforza la sua presenza nelle malattie rare con il lancio della specialità medicinale VOTUBIA